https://ntp.niehs.nih.gov/go/18977

Water disinfection model (Bromodichloromethane): Target Organs and Levels of Evidence for GMM-05

Toxicology Studies of Bromodichloromethane (CASRN 75-27-4) in Genetically Modified (FVB Tg.AC Hemizygous) Mice (Dermal, Drinking Water, and Gavage Studies) and Carcinogenicity Studies of Bromodichloromethane in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Drinking Water and Gavage Studies)

Chemical (Study Title)
CASRN 		Peer Review Date Route/Exposure Levels Study Laboratory
Water disinfection model (Bromodichloromethane)
75-27-4 		09/27/2005 Topical Application
0, 64, 128, and 256 mg/kg		 Battelle Columbus Laboratory

Levels of evidence information for Dermal and Genetic Toxicology Studies of Bromodichloromethane in Tg.AC Hemizygous Mice
  Male Tg.AC Hemizygous Mice Female Tg.AC Hemizygous Mice
  26 Weeks 39 Weeks 26 Weeks 39 Weeks
Neoplastic Lesions None None None None
Non-Neoplastic Lesions None None None None



Chemical (Study Title)
CASRN 		Peer Review Date Route/Exposure Levels Study Laboratory
Water disinfection model (Bromodichloromethane)
75-27-4 		09/27/2005 Dosed-Water
0, 175, 350, or 700 mg/L		 Battelle Columbus Laboratory

Levels of evidence information for Drinking Water and Genetic Toxicology Studies of Bromodichloromethane in p53 Haploinsufficient Mice
  Male P53 +/- (C57BL/6) Mice Female P53 +/- (C57BL/6) Mice
  26 Weeks 42 Weeks 26 Weeks 42 Weeks
Levels of Evidence No Evidence No Evidence No Evidence No Evidence
Neoplastic Lesions None None None None
Non-Neoplastic Lesions
  • Kidney: tubule degeneration
  • Kidney: tubule degeneration
  • Liver: hepatocyte fatty change
 None

Levels of evidence information for Drinking Water and Genetic Toxicology Studies of Bromodichloromethane in Tg.AC Hemizygous Mice
  Male Tg.AC (FVB/N) Hemizygous Mice Female Tg.AC (FVB/N) Hemizygous Mice
  26 Weeks 42 Weeks 26 Weeks 42 Weeks
Neoplastic Lesions None None None None
Non-Neoplastic Lesions
  • Kidney: nephropathy; tubule degeneration
  • Kidney: nephropathy
  • Liver: hepatocyte fatty change; hepatocyte cytoplasmic vacuolization
  • Liver: hepatocyte fatty change



Chemical (Study Title)
CASRN 		Peer Review Date Route/Exposure Levels Study Laboratory
Water disinfection model (Bromodichloromethane)
75-27-4 		09/27/2005 Gavage
0, 25, 50, or 100 mg/kg		 Battelle Columbus Laboratory

Levels of evidence information for Gavage and Genetic Toxicology Studies of Bromodichloromethane in p53 Haploinsufficient Mice
  Male P53 +/- (C57BL/6) Mice Female P53 +/- (C57BL/6) Mice
  26 Weeks 41 Weeks 26 Weeks 41 Weeks
Levels of Evidence No Evidence No Evidence No Evidence No Evidence
Neoplastic Lesions None None None None
Non-Neoplastic Lesions
  • Kidney: tubule degeneration
  • Kidney: tubule degeneration
  • Liver: hepatocyte fatty change
  • Liver: hepatocyte fatty change


Levels of evidence information for Gavage and Genetic Toxicology Studies of Bromodichloromethane in Tg.AC Hemizygous Mice
  Male Tg.AC (FVB/N) Hemizygous Mice Female Tg.AC (FVB/N) Hemizygous Mice
  26 Weeks 41 Weeks 26 Weeks 41 Weeks
Neoplastic Lesions None None
  • Forestomach: multiple squamous cell papilloma 3/15 5/15 6/15 11/15
  • Forestomach: multiple squamous cell papilloma 1/10 6/10 5/10 9/10
Non-Neoplastic Lesions
  • Kidney: tubule degeneration
  • Kidney: tubule degeneration
  • Liver: hepatocyte fatty change; hepatocyte cytoplasmic vacuolization
  • Liver: hepatocyte fatty change; hepatocyte cytoplasmic vacuolization